4 results on '"Anjan K. Pradhan"'
Search Results
2. Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic
- Author
-
Devanand Sarkar, Xiang-Yang Wang, Swadesh K. Das, Paul B. Fisher, Anjan K. Pradhan, Praveen Bhoopathi, Luni Emdad, and Sarmistha Talukdar
- Subjects
0301 basic medicine ,Mezerein ,Cancer Research ,Programmed cell death ,medicine.medical_treatment ,Antineoplastic Agents ,Apoptosis ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,Clinical Trials, Phase II as Topic ,0302 clinical medicine ,Neoplasms ,Autophagy ,Animals ,Humans ,Medicine ,Cell Death ,Clinical Trials, Phase I as Topic ,Subtraction hybridization ,business.industry ,Interleukins ,Melanoma ,medicine.disease ,030104 developmental biology ,Cytokine ,chemistry ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,business - Abstract
Apoptosis and autophagy play seminal roles in maintaining organ homeostasis. Apoptosis represents canonical type I programmed cell death. Autophagy is viewed as pro-survival, however, excessive autophagy can promote type II cell death. Defective regulation of these two obligatory cellular pathways is linked to various diseases, including cancer. Biologic or chemotherapeutic agents, which can reprogram cancer cells to undergo apoptosis- or toxic autophagy-mediated cell death, are considered effective tools for treating cancer. Melanoma differentiation associated gene-7 (mda-7) selectively promotes these effects in cancer cells. mda-7 was identified more than two decades ago by subtraction hybridization showing elevated expression during induction of terminal differentiation of metastatic melanoma cells following treatment with recombinant fibroblast interferon and mezerein (a PKC activating agent). MDA-7 was classified as a member of the IL-10 gene family based on its chromosomal location, and the presence of an IL-10 signature motif and a secretory sequence, and re-named interleukin-24 (MDA-7/IL-24). Multiple studies have established MDA-7/IL-24 as a potent anti-cancer agent, which when administered at supra-physiological levels induces growth arrest and cell death through apoptosis and toxic autophagy in a wide variety of tumor cell types, but not in corresponding normal/non-transformed cells. Furthermore, in a phase I/II clinical trial, MDA-7/IL-24 administered by means of a non-replicating adenovirus was well tolerated and displayed significant clinical activity in patients with multiple advanced cancers. This review examines our current comprehension of the role of MDA-7/IL-24 in mediating cancer-specific cell death via apoptosis and toxic autophagy.
- Published
- 2020
3. SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide
- Author
-
Anjan K. Pradhan, Sneha Singh, and Soumen Chakraborty
- Subjects
Transcription, Genetic ,Lysine ,SUMO protein ,Fluorescent Antibody Technique ,Apoptosis ,Proto-Oncogene Mas ,Antileukemic agent ,Arsenicals ,Immunoenzyme Techniques ,Transactivation ,chemistry.chemical_compound ,Arsenic Trioxide ,Arsenic trioxide (ATO) ,Tumor Cells, Cultured ,Arsenic trioxide ,Ovarian Neoplasms ,Reverse Transcriptase Polymerase Chain Reaction ,Oxides ,Cell biology ,DNA-Binding Proteins ,Gene Expression Regulation, Neoplastic ,Biochemistry ,Female ,Transcriptional Activation ,Acute promyelocytic leukemia ,Chromatin Immunoprecipitation ,Blotting, Western ,SUMO-1 Protein ,bcl-X Protein ,Antineoplastic Agents ,Biology ,Real-Time Polymerase Chain Reaction ,SIRT1 ,Proto-Oncogenes ,medicine ,Humans ,Immunoprecipitation ,RNA, Messenger ,Ligase activity ,Molecular Biology ,Bcl-xL ,Sumoylation ,Cell Biology ,medicine.disease ,MDS1 and EVI1 Complex Locus Protein ,EVI1 ,PIASy ,chemistry ,Cancer cell ,Mutagenesis, Site-Directed ,Transcription Factors - Abstract
Aberrant expression of the proto-oncogene EVI1 (ecotropic virus integration site1) has been implicated not only in myeloid or lymphoid malignancies but also in colon, ovarian and breast cancers. Despite its importance in oncogenesis, the regulatory factors and mechanisms that potentiate the function of EVI1 and its consequences are partially known. Here we demonstrated that EVI1 is post-translationally modified by SUMO1 at lysine residues 533, 698 and 874. Although both EVI1 and SUMO1 were found to co-localize in nuclear speckles, the sumoylation mutant of EVI1 failed to co-localize with SUMO1. Sumoylation abrogated the DNA binding efficiency of EVI1 and also affected EVI1 mediated transactivation. The SUMO ligase PIASy was found to play a bi-directional role on EVI1, PIASy enhanced EVI1 sumoylation and augmented sumoylated EVI1 mediated repression. PIASy was also found to interact with EVI1 and impaired EVI1 transcriptional activity independent of its ligase activity. Arsenic trioxide (ATO) known to act as an antileukemic agent for acute promyelocytic leukemia (APL) not only enhanced EVI1 sumoylation but also enhanced the co-localization of EVI1 and SUMO1 in nuclear bodies distinct from PML nuclear bodies. ATO treatment also affected the Bcl-xL protein expression in EVI1 positive cell line. Thus, the results showed that arsenic treatment enhanced EVI1 sumoylation, deregulated Bcl-xL, which eventually may induce apoptosis in EVI1 positive cancer cells. The study for the first time explores and reports sumoylation of EVI1, which plays an essential role in regulating its function.
- Published
- 2013
4. EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1
- Author
-
Soumen Chakraborty, Anjan K. Pradhan, Sneha Singh, and Nivedita Kuila
- Subjects
Transcriptional Activation ,Chromatin Immunoprecipitation ,Blotting, Western ,Biophysics ,Biology ,Biochemistry ,Mice ,Sirtuin 1 ,Structural Biology ,Cell Line, Tumor ,Proto-Oncogenes ,Genetics ,Animals ,Humans ,Luciferase ,Promoter Regions, Genetic ,Molecular Biology ,Zinc finger ,Reverse Transcriptase Polymerase Chain Reaction ,Myeloid leukemia ,Acetylation ,Promoter ,Molecular biology ,MDS1 and EVI1 Complex Locus Protein ,Up-Regulation ,DNA-Binding Proteins ,HEK293 Cells ,PCAF ,RNA Interference ,Histone deacetylase ,Tumor Suppressor Protein p53 ,K562 Cells ,Chromatin immunoprecipitation ,Protein Binding ,Transcription Factors - Abstract
EVI1 (Ecotropic Viral Integration site I), which was originally identified as a site of viral integration in murine myeloid tumors, encodes a complex protein required for embryogenesis. The gene is known to express inappropriately in many types of human myeloid leukemias and solid tumors. Forced expression of EVI1 in murine hematopoietic precursor cells lead to abnormal differentiation and increased proliferation. EVI1 encodes two sets of zinc finger domains due to which it behaves as a transcriptional factor. However, except a few, the targets of EVI1 are not well understood and hence also the mechanism by which it initiates oncogenesis is not very clear. In this report, we show that SIRT1, a histone deacetylase is a direct target of EVI1. In vivo chromatin immunoprecipitation assay revealed that EVI1 binds to the promoter region of SIRT1 approximately 1 kb upstream of the transcription start site. The functionality of the site was deduced by luciferase assay which showed that EVI1 significantly increases the SIRT1 promoter activity. SIRT1 was also found to be up regulated in cell lines and in chronic myeloid leukemia patient samples where EVI1 was detected. Over expression of SIRT1 in cells shows that it interacts with EVI1 and this interaction lead to the deacetylation of the protein. Upon deacetylation the stability of EVI1 was found to be affected which was negatively regulated by nicotinamide (NAM). Our results thus identify an EVI1-SIRT1 axis in the regulation of EVI1 activity suggesting a possible role of SIRT1 in EVI1 positive neoplasms.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.